[Form 4] AVANOS MEDICAL, INC. Insider Trading Activity

Rhea-AI Filing Summary

Avanos Medical, Inc. executive Kerr W. Holbrook, the SVP and Chief Commercial Officer, reported open-market sales of company common stock. On 11/18/2025, he sold a total of 15,000 shares of Avanos Medical common stock in several transactions at prices ranging from $11.00 to $11.02 per share. After these sales, Holbrook directly beneficially owned 83,860 shares of Avanos Medical common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Holbrook Kerr

(Last) (First) (Middle)

5405 WINDWARD PKWY

(Street)

ALPHARETTA GA 30004

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AVANOS MEDICAL, INC. [ AVNS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/18/2025		S		13,834	D	$11	85,026	D
Common Stock	11/18/2025		S		100	D	$11.005	84,926	D
Common Stock	11/18/2025		S		761	D	$11.01	84,165	D
Common Stock	11/18/2025		S		305	D	$11.02	83,860	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ John Hurley, as attorney-in-fact for Kerr W. Holbrook	11/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did AVNS report for Kerr W. Holbrook?

AVNS reported that Kerr W. Holbrook, its SVP and Chief Commercial Officer, sold 15,000 shares of Avanos Medical common stock in open-market transactions.

On what date did Kerr W. Holbrook sell AVNS shares?

The reported sales of Avanos Medical (AVNS) shares by Kerr W. Holbrook occurred on 11/18/2025.

At what prices were Kerr W. Holbrook’s AVNS shares sold?

The AVNS common stock sales were executed at prices of $11.00, $11.005, $11.01, and $11.02 per share.

How many AVNS shares did Kerr W. Holbrook sell in each transaction?

On 11/18/2025, Kerr W. Holbrook sold 13,834 shares at $11.00, 100 shares at $11.005, 761 shares at $11.01, and 305 shares at $11.02 of Avanos Medical common stock.

How many AVNS shares does Kerr W. Holbrook own after the transactions?

Following the reported sales, Kerr W. Holbrook directly beneficially owned 83,860 shares of Avanos Medical common stock.

What is Kerr W. Holbrook’s role at Avanos Medical (AVNS)?

Kerr W. Holbrook is an officer of Avanos Medical, Inc., serving as SVP, Chief Commercial Officer.

Was the Form 4 for AVNS filed by a single reporting person?

Yes. The Form 4 indicates it was filed by one reporting person, covering Kerr W. Holbrook’s transactions.